<DOC>
	<DOCNO>NCT00003343</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether mitoxantrone prednisone effective without prinomastat treat patient metastatic prostate cancer . PURPOSE : Randomized phase III trial determine effectiveness mitoxantrone prednisone without prinomastat treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Chemotherapy Treating Patients Who Have Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare symptomatic progression free survival among patient metastatic , hormone refractory prostate cancer receive one two dos matrix metalloprotease inhibitor AG3340 placebo initially combination mitoxantrone prednisone provision subsequent change therapy . II . Compare symptomatic response , quality life , serologic ( PSA ) response , PSA progression free survival , radiographic response , radiographic progression free survival , one year survival , overall survival patient . III . Evaluate safety AG3340 regimen combination combination therapy administer subsequent first line patient population . IV . Evaluate population pharmacokinetics AG3340 give treatment regimen . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients receive matrix metalloprotease inhibitor AG3340 ( one two dosage ) placebo , orally twice day , begin day 1 . Patients receive mitoxantrone intravenous infusion day 1 prednisone orally twice daily begin day 1 . Treatment course repeat every 3 week absence unacceptable toxicity . Mitoxantrone and/or prednisone may discontinue switch investigator 's discretion . PROJECTED ACCRUAL : There 525 patient accrue study approximately 50 center .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Prinomastat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic , hormone refractory prostate cancer Must undergone prior orchiectomy treatment LHRH analog Prior treatment antiandrogen agent ( e.g. , flutamide bicalutamide ) optional Castrate serum testosterone great 50 ng/mL PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal Renal : Not specify Other : Effective contraception require patient For information regard protocol , please call 18888496482 . Clinical site throughout United States Canada . PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy prostate cancer Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : See Disease Characteristics At least 6 week since bicalutamide At least 4 week since flutamide Radiotherapy : At least 2 week since prior radiotherapy Surgery : See Disease Characteristics At least 3 week since prior surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage IV prostate cancer</keyword>
</DOC>